SCHEMBL8622944

SCHEMBL8622944

CCOC(=O)c1cncc(-c2ccc(Br)cc2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 3/20 0.57
CYP2C9 P11712 2/20 0.57
KMT2A Q03164 3/20 0.53
MAPT P10636 2/20 0.53
HTT P42858 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
SIRT2 Q8IXJ6 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.50
IDO1 P14902 1/20 0.48
POLB P06746 1/20 0.48
TSHR P16473 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
HSD17B10 Q99714 1/20 0.48
TARBP2 Q15633 1/20 0.48
MEN1 O00255 2/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
CYP1A2 P05177 2/20 0.47
KDM4E B2RXH2 1/20 0.47
RECQL P46063 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL640338 0.87 CYP2C9 (0.59) CYP2C19CYP2C9MAPTHTTSMN1; SMN2
SCHEMBL4908272 0.86 LMNA (0.59) CYP2C19CYP2C9KMT2AMAPTSMN1; SMN2
SCHEMBL5372083 0.85 CYP2C9 (0.65) CYP2C19CYP2C9KMT2AMAPTHTT
SCHEMBL640295 0.84 CYP11B1 (0.60) CYP2C19CYP2C9KMT2AMAPTL3MBTL1
SCHEMBL640459 0.83 CYP2C9 (0.55) CYP2C19CYP2C9CYP1A2CYP3A4
SCHEMBL158686 0.83 CYP2C19 (0.70) CYP2C19CYP2C9MAPTHTTSMN1; SMN2
SCHEMBL29597594 0.83 CYP2C19 (0.70) CYP2C19CYP2C9MAPTHTTSMN1; SMN2
SCHEMBL14017822 0.83 CYP2C19 (0.57) CYP2C19CYP2C9KMT2AMAPTSMN1; SMN2
SCHEMBL640303 0.82 MAOB (0.54) CYP2C19CYP2C9KMT2AMAPTMEN1
SCHEMBL6705884 0.81 CA12 (0.61) CYP2C19CYP2C9KMT2AMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5714496-A TREATMENT OF HYPERCHOLESTEROLEMIA AND ATHERSCLEROSIS ZENECA LIMITED (GB) 1998-02-03 US disclosed
EP-0656897-B1 QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS ZENECA LTD (GB) 1998-01-07 EP disclosed
EP-0656897-A1 QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS ZENECA LIMITED (GB) 1995-06-14 EP disclosed
WO-1994005660-A1 QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS ZENECA LIMITED (GB) 1994-03-17 WO disclosed